Petmed Express (PETS)
NASDAQ:PETS
Want to see PETS full AI Analyst Report?
Top Page
Petmed Express
(NASDAQ:PETS)
Select Model
Select Model
Rating:41Neutral
Price Target:
$2.00
▲(12.99% Upside)
Action:Reiterated
Date:02/07/26
The score is driven primarily by sharply deteriorating financial performance (losses, contracting revenue, and cash burn). Technicals also remain weak with bearish trend indicators despite oversold readings. Valuation is difficult to support due to negative earnings, and corporate events add incremental risk due to the Nasdaq compliance notice.
Positive Factors
Direct-to-Consumer Pharmacy Model
PetMed Express operates a direct-to-consumer pet pharmacy with pharmacy fulfillment and veterinarian/manufacturer relationships. That model supports recurring prescription orders, predictable replenishment behavior and lower reliance on third-party retail, a durable revenue base if retention and fulfillment remain stable.
Negative Factors
Deteriorating Profitability
Revenue and profitability have materially reversed: a persistent revenue decline and a large net loss signal a break in earnings power. Gross margin (~29%) no longer covers operating costs, implying the core model is under strain and earnings recovery will require structural demand or cost improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Direct-to-Consumer Pharmacy Model
PetMed Express operates a direct-to-consumer pet pharmacy with pharmacy fulfillment and veterinarian/manufacturer relationships. That model supports recurring prescription orders, predictable replenishment behavior and lower reliance on third-party retail, a durable revenue base if retention and fulfillment remain stable.
Read all positive factors
Petmed Express (PETS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$45.37M
Dividend YieldN/A
Average Volume (3M)83.39K
Price to Earnings (P/E)―
Beta (1Y)1.29
Revenue Growth-26.05%
EPS Growth-19236.81%
CountryUS
Employees287
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding21,400,496
10 Day Avg. Volume83,849
30 Day Avg. Volume83,390
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)1.01
Price to Sales (P/S)0.38
P/FCF Ratio-218.47
Enterprise Value/Market Cap0.42
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.36
Enterprise Value/Ebitda-0.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Petmed Express Business Overview & Revenue Model
Company Description
PetMed Express, Inc., together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers...
How the Company Makes Money
PetMed Express makes money primarily by selling pet medications and health-related products directly to consumers through its e-commerce storefront. Revenue is generated on a per-order basis from (1) prescription medications, where the company dis...
Petmed Express Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 182.67M | 226.97M | 274.10M | 256.58M | 273.42M | 303.58M |
| Gross Profit | 52.94M | 69.14M | 77.71M | 71.01M | 75.34M | 84.32M |
| EBITDA | -48.38M | 6.71M | 783.00K | 10.99M | 29.81M | 32.96M |
| Net Income | -64.87M | -6.27M | -7.46M | 5.14M | 21.10M | 23.92M |
Balance Sheet | ||||||
| Total Assets | 87.97M | 148.70M | 169.88M | 170.00M | 176.32M | 187.50M |
| Cash, Cash Equivalents and Short-Term Investments | 26.91M | 54.72M | 55.30M | 104.09M | 111.08M | 118.72M |
| Total Debt | 652.00K | 996.00K | 1.45M | 995.00K | 0.00 | 0.00 |
| Total Liabilities | 55.20M | 63.57M | 73.15M | 60.04M | 34.13M | 46.22M |
| Stockholders Equity | 32.77M | 85.13M | 96.73M | 109.97M | 142.19M | 141.28M |
Cash Flow | ||||||
| Free Cash Flow | -22.92M | -395.00K | -194.00K | 22.54M | 16.75M | 37.64M |
| Operating Cash Flow | -16.64M | 4.72M | 4.32M | 27.80M | 18.50M | 40.08M |
| Investing Cash Flow | -6.28M | -5.11M | -40.67M | -10.26M | -1.75M | -2.43M |
| Financing Cash Flow | -241.00K | -181.00K | -12.44M | -24.54M | -24.38M | -22.69M |
Petmed Express Technical Analysis
Negative
1.77
Price Trends
2.31
Negative
2.68
Negative
2.67
Negative
Market Momentum
-0.04
Positive
34.40
Neutral
17.79
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PETS, the sentiment is Negative. The current price of 1.77 is below the 20-day moving average (MA) of 2.25, below the 50-day MA of 2.31, and below the 200-day MA of 2.67, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 34.40 is Neutral, neither overbought nor oversold. The STOCH value of 17.79 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PETS.
Petmed Express Risk Analysis
Petmed Express disclosed 33 risk factors in its most recent earnings report. Petmed Express reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Petmed Express Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $202.64M | ― | -172.30% | ― | -6.23% | -25.01% | |
53 Neutral | $177.70M | -4.05 | -48.20% | ― | 7336.90% | 49.64% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $306.17M | -0.63 | 309.79% | ― | -35.61% | -68.92% | |
43 Neutral | $50.08M | -6.67 | 8.26% | ― | -12.80% | -1.34% | |
41 Neutral | $45.37M | -1.59 | -122.10% | ― | -26.05% | -19236.81% |
* Healthcare Sector Average
PETS
Petmed Express
2.12
-1.50
-41.44%
YI
111
5.70
-2.23
-28.12%
LFMD
LifeMD
4.19
-7.35
-63.69%
SRZN
Surrozen
26.37
18.72
244.71%
ADAG
Adagene
3.75
1.93
106.04%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.